Αρχική World News FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have... World News FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection Από Ogkologos - 20 Μαρτίου, 2025 973 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... 10 Μαρτίου, 2026 Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations 13 Αυγούστου, 2018 EMA Recommends Granting a Marketing Authorisation for Sugemalimab 21 Ιουνίου, 2024 Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... 23 Απριλίου, 2025 Φόρτωση περισσοτέρων HOT NEWS How to Spend Time with Friends and Family Now that COVID... EMA Recommends Granting a Marketing Authorisation for Azacitidine 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... Foodie Fridays-Gazpacho: A Favorite Summer Soup